AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00264459 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass pollen formulation
Description: Solution for sublingual application containing allergen extracts of 6 grass pollen species (Holcus lanatus, Dactylus glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca pratensis) pollen allergen extract.~The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter.
Study NCT03436615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB206 12%
Description: Once or twice daily
Study NCT03436615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once or twice daily
Study NCT03775876 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder Arthroscopy
Description: patients in both groups are programmed for an elective shoulder arthroscopy surgery
Study NCT03775876 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional Block
Description: patients in both groups received regional block for anesthesia: brachial plexus blockade was performed using the interscalene approach under ultrasound combined to nerve stimulation. 20 ml ropivacaine 0.375% were injected.
Study NCT03775876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol 10mg/ml was used for sedation as described in the arms section
Study NCT03775876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine was diluted to 4mcg/ml and used for sedation as described in the arms section
Study NCT03775876 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: BIS
Description: sedation level was monitored using bispectral index to achieve values described in the arms group
Study NCT03607331 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular vagus nerve stimulation
Description: Auricular vagus nerve stimulation is a typical representative of TCM modernization.
Study NCT03607331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Citalopram is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class.It has U.S. Food and Drug Administration approval to treat major depression.
Study NCT05936320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information leaflets with illustrations about hearing aid functions
Description: The information leaflet contains written information with simple illustrations about placement in noisy environments, how to use a telecoil and about directional microphones function in hearing aids. The time spent presenting the information leaflet was approximately ten minutes.
Study NCT05936320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information leaflets with only text about hearing aid functions
Description: The information leaflet contains written information about placement in noisy environments, how to use a telecoil and about directional microphones function in hearing aids. The time spent presenting the information leaflet was approximately ten minutes.
Study NCT05156541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon gamma human recombinant (IFN-G)
Description: received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
Study NCT01469000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: 250 mg orally once per day. Number of cycles until disease progression or unacceptable toxicity develops.
Study NCT01469000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: 250 mg orally once per day. Number of cycles until disease progression or unacceptable toxicity develops.
Study NCT01469000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m² IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.
Study NCT04033419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: memantine dose~* Week 1: 5 mg dose once daily~* Week 2: 5 mg dose twice daily~* Week 3: 5 mg each morning/10 mg each evening~* Week 4 through the end of Chemotherapy: 10 mg dose twice daily~* Total duration: 12 - 26 weeks (depending on chemotherapy regimen)
Study NCT00223899 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VCL-IM01 (encoding IL-2) with Electroporation
Description: IL-2-encoding plasmid formulated in phosphate-buffered saline at 0.5 mg/mL, 1.5 mg/mL, and 5.0 mg/mL (VCL-IM01) intratumorally injected and followed by electroporation with Inovio MedPulser® 1.0 cm array with needles up to 3 cm long (one 6-pulse cycle per tumor).
Study NCT04178980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin in relapsing remitting multiple sclerosis
Description: Simvastatin use as adjuvant thearapy in relapsing remitting multiple sclerosis
Study NCT04178980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin in relapsing remitting multiple sclerosis
Description: Simvastatin use as adjuvant thearapy in relapsing remitting multiple sclerosis
Study NCT00757731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: milnacipran
Description: hard capsule
Study NCT00757731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: hard capsule
Study NCT02276586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Horizontal Tooth preparation
Description: Round parallel chamfer diamond burs were used for teeth preparation; coarse first (151 micron) and extra-fine after (25 micron)
Study NCT02276586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertical Tooth preparation
Description: Long flame diamond burs were used for teeth preparation; coarse first (151 micron) and extra-fine after (25 micron)
Study NCT02662647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m²/day for 5 days
Study NCT03079479 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle Strenght assesment
Description: Muscle Strenght assesment of the hip muscles
Study NCT03079479 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 2D Kinematics Analysis
Description: 2D Kinematics Analysis of the gait
Study NCT02026063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: Telotristat etiprate tablet (250 mg)
Study NCT00723788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI of the abdomen
Description: Multiple MRI pulse sequences of the abdomen
Study NCT00264459 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Comparator
Description: Solution for sublingual application containing Placebo. The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter.
Study NCT00052195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SRL-172
Description: 5 doses of 0.1mL vaccine or placebo given intradermally over 12-months
Study NCT00052195 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SRL-172
Description: 5 doses of 0.1mL vaccine or placebo given intradermally over 12-months
Study NCT01578031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive Airway Pressure During Sleep (ResMed S9 Elite)
Description: Positive airway pressure during sleep (ResMed S9 Elite).
Study NCT01578031 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual care.
Study NCT03219073 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS using tDCS device
Description: Active tDCS using tDCS device is a noninvasive brain stimulation technique that utilizes low amplitude direct currents applied via scalp electrodes to apply currents to the brain and modulate the level of cortical excitability. tDCS applied over the dorsolateral prefrontal and motor cortex has been reported to be able to decrease pain sensation and to increase pain threshold in healthy subjects and is effective in reducing central chronic pain in PwMS.
Study NCT03219073 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM tDCS using tDCS device
Description: SHAM tDCS emulates active tDCS in all but the actual stimulation. Electrodes of the tDCS device are placed in the same place as with active tDCS however no current is activated.
Study NCT02238847 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WallFlex™ Biliary RX Fully Covered/Uncovered Stent System
Description: Reintervention can occur in Arm 1 or Arm 2 with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System
Study NCT03887130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral vinorelbine
Description: Oral vinorelbine 60 mg/m² on day 1 \& day 8, for cycle 1, and then 80 mg/m² on day 1 \& day 8, every 3 weeks for subsequent cycles
Study NCT03887130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m² twice a day (2000 mg/m² daily) from day 1 to day 14
Study NCT03887130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine 1250 mg/m²
Description: Gemcitabine 1250 mg/m² on day 1 \& day 8
Study NCT03887130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine 1000 mg/m²
Description: Gemcitabine: 1000 mg/m² on day 1 \& 8
Study NCT03887130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m² on day 1
Study NCT03887130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m² on day 1
Study NCT02182349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA soft gelatin capsule
Study NCT02182349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-BI 201335 NA radiolabelled drug
Study NCT03687502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur hexafluoride lipid-type A microspheres
Description: Contrast Enhanced Ultrasound of the appendix
Study NCT02497001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI 320/14.4/9.6 μg
Description: Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler \[MDI\])
Study NCT02497001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFF MDI (PT003) 14.4/9.6 μg
Description: Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)
Study NCT02497001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFF MDI (PT009) 320/9.6 μg
Description: Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)
Study NCT02497001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort® Turbuhaler® (TBH) Inhalation Powder
Study NCT02080793 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Study NCT00705263 — intervention group
Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2b (SCH 54031)
Description: Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
Study NCT00705263 — intervention group
Intervention type: DRUG
Intervention: Ribavirin (SCH 18908)
Description: Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
Study NCT03898063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 90 DAYS film
Description: the intervention conditions include exposure to a film, 90 DAYS (approx 20 minutes long), an entertainment film detailing a woman's decision to tell her romantic partner that she is HIV-positive.
Study NCT03898063 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV pamphlet on disclosure
Description: A standard-of-care brochure given to newly diagnosed HIV patients about the importance of status disclosure
Study NCT01902732 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Implantation of valves (IBV)
Description: Implantation of intrabronchial valves in the most emphysematous destroyed and hyperinflated lung lobe improves the elastic recoisl of the samll airways by a reduction in lung volume and thus leading to more ergonomic breathing mechanics and diaphragm function. This positive effect is observed particularly in patients with low interlobar collateral ventilation that can be quantified by CT fissure analysis and/or catheter-based measurement.
Study NCT02921451 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Restorelle Smartmesh
Description: Patients will have surgery using the device, Restorelle Smartmesh, for treatment of uterine prolapse.
Study NCT03423498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: toe-spread-out exercise
Description: The therapeutic intervention lasted 14 days and focused on doing the TSO exercise. This exercise was performed unilaterally under the supervision of a qualified physiotherapist. The starting position of the TSO exercise was the sitting position with the knee joint and hip bent at 90 degrees. The exercise consisted of 3 consecutive phases: dorsiflexion of the toes keeping the metatarsal heads and the heel on the ground, moving the fifth toe down and in a lateral direction, moving the big toe down and abduction. The final position needs to be maintained for 5 seconds. The whole sequence was repeated 200 times a day.
Study NCT02899156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flumazenil
Study NCT02899156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% normal saline
Study NCT01864616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Study NCT02315924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simultaneous coronary and cerebral intervention
Description: Simultaneous strategy is considered that coronary and cerebral intervention will be performed via the same access and within the same day.
Study NCT02315924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: staged coronary and cerebral intervention
Description: Staged strategy was intended that coronary or cerebral intervention will be performed within 7 days from the first procedure.
Study NCT02315924 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: staged coronary and cerebral intervention
Description: Staged strategy was intended that coronary or cerebral intervention will be performed within 7 days from the first procedure.
Study NCT03754907 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endocutter stapler
Description: Endocutter ETS 35, ETS Flex 45 stapler, and the Echelon Flex Powered ENDOPATH Stapler with 2.5- or 3.5-mm staples (Johnson \& Johnson K.K., Tokyo, Japan)
Study NCT03754907 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suture material
Description: absorbable suture material is used to perform hand-sewn anastomosis in an end-to-end manner.
Study NCT01653041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study NCT02058602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of Idiopathic Pulmonary Fibrosis over a period of up to 6 months
Description: Patients are receiving no treatment on this study and there is no investigational product involved.
Study NCT01779284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost/timolol therapy
Description: Evaluation of 24-hour pressure efficacy with travoprost/timolol therapy after 3 months of chronic dosing
Study NCT01779284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost/Timolol therapy
Description: Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
Study NCT03430986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM® VOLUMA® with Lidocaine
Description: Treatment with JUVÉDERM® VOLUMA® with Lidocaine injectable gel with optional treatment 8 weeks later.
Study NCT03430986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No-treatment control
Description: No treatment during the control period.
Study NCT03022942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GROUP Costal mobilization & Diaphragm Release
Description: Costal mobilization technique (Rib raising): The patient will be lying. The Therapist supports the last four pulps of both hands at the rib angles, gently traverses the rib angles in the posterior-anterior direction, using the stretcher as a lever to facilitate the elevation of the costal angles. Siting: The Therapist hugs the patient by supporting the ribs of the fingers at the rib angles, gently traverses the rib angles bilaterally in the anterior-lateral direction. Manual Diaphragm Release Technique: The therapist makes manual contact with the underside of the costal border of the common cartilage of the last rib. In the inspiratory phase, the therapist draws the points of contact with both hands in a cephalad direction and slightly Accompanying the movement of the rib cage.
Study NCT02364336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Study NCT00522925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS433540
Description: 200mg capsule, once daily for 28 days
Study NCT00522925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule, once daily for 28 days
Study NCT03022942 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GROUP Manual Diaphragm Release
Description: The therapist makes manual contact with the underside of the costal border of the common cartilage of the last rib. In the inspiratory phase, the therapist draws the points of contact with both hands in a cephalad direction and slightly Accompanying the movement of the rib cage.
Study NCT01455103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936559 (Anti-PD-L1)
Description: Solution, Intravenous infusion, 1 mg/kg, Every 2 weeks, Up to 2 years, depending on response
Study NCT01455103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936559 (Anti-PD-L1)
Description: Solution, Intravenous infusion, 3 mg/kg, Every 2 weeks, Up to 2 years, depending on response
Study NCT01455103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936559 (Anti-PD-L1)
Description: Solution, Intravenous infusion, 10 mg/kg, Every 2 weeks, Up to 2 years, depending on response
Study NCT05104047 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moxibustion - Traditional (Active)
Description: Traditional Moxibustion (Moxa) is a technique in which the herb, artemisia, in a cigar shape (pole moxa) is lit (burned) and applied over specific acupuncture points which follows a specific protocol aimed at reducing neuropathic lower limb pain/discomfort.
Study NCT05104047 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moxibustion - Smokeless - (Active)
Description: Smokeless Moxibustion uses the same technique as traditional moxa however, the moxa is smokeless. Smokeless moxa allows for use in a broad range of treatment settings. The protocol is aimed at reducing neuropathic lower limb pain/discomfort.
Study NCT05104047 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Moxibustion
Description: Participants receive Placebo Moxibustion - a protocol that mimics the active protocol but is not active.
Study NCT03132584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: The chemotherapy drugs will be given in the hospital. During the first cycle of treatment, participants will stay in the hospital until their blood counts have recovered after treatment. During cycles 2 and 3, participants may go home after chemotherapy if they are doing well. The length of each cycle is 28 days~- Via IV Day 3
Study NCT03132584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: * The chemotherapy drugs will be given in the hospital. During the first cycle of treatment, participants will stay in the hospital until their blood counts have recovered after treatment. During cycles 2 and 3, participants may go home after chemotherapy if they are doing well. The length of each cycle is 28 days~* Alemtuzumab will be administered as follows:~  * IV Day 1~ * IV Day 2~ * Target dose IV on Day 3 and 4
Study NCT01699256 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guideline implementation as usual
Description: Newsletters and Invitation to Meetings
Study NCT01699256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced guideline implementation strategy
Description: Enhanced guideline implementation strategy
Study NCT01412957 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Best Supportive Care (BSC)
Description: BSC was defined as the best palliative care available as judged appropriate by the investigator and according to institutional guidelines and could include antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy as clinically indicated.
Study NCT01412957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Description: BSC was defined as the best palliative care available as judged appropriate by the investigator and according to institutional guidelines and could include antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy as clinically indicated.
Study NCT01412957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Administered intravenously